| Return Reference | Explanation |
|---|---|
| FORM 990, PART VI, SECTION A, LINE 6: | THE ORGANIZATION HAS MEMBERS THAT ARE ENGAGED IN THE PRODUCTION AND/OR DEVELOPMENT OF PHARMACEUTICAL PRODUCTS. |
| FORM 990, PART VI, SECTION A, LINE 7A: | THE MEMBERS HAVE THE RIGHT TO VOTE ON THE ADMISSION OF NEW MEMBERS, THE APPOINTMENT OR ELECTION OF DIRECTORS, THE REMOVAL OF DIRECTORS AND THE ADOPTION, AMENDMENT, CHANGE OR REPEAL OF THE ORGANIZATION'S ORGANIZING DOCUMENTS. |
| FORM 990, PART VI, SECTION B, LINE 11B: | THE ORGANIZATION'S FORM 990 IS PROVIDED TO THE BOARD FOR REVIEW PRIOR TO FILING. |
| FORM 990, PART VI, SECTION B, LINE 12C: | The Corporation's Board has adopted a conflict of interest policy that requires officers and directors of the Corporation to, on an annual basis, sign a statement affirming that they have received a copy of the policy, have read and understand the policy, and have agreed to comply with the policy. |
| FORM 990, PART VI, SECTION B, LINE 15A: | 990's were reviewed for comparable fees for consultants who serve as CEO, Executive Director or Secretariat; Consultant hourly rates were also compared to hourly rates of comparable consultants in life sciences. The Chair and Treasurer reviewed and approved the hourly rate and based upon the number of hours spent working in 2022 and based upon the strategic work plan for 2023 a target range of hours was arrived at. The rate was approved by the Finance Committee and by the board. A written contract was executed in 2022. |
| FORM 990, PART VI, SECTION B, LINE 19: | The Corporation makes these documents available upon written request to the Secretary. |
| Software ID: | |
| Software Version: |